Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration

Experimental and Molecular Medicine

Volumn 43, Issue 4, 2011, Pages 179-188

  Chung, Ji Hyung ^a,b,c,d   Im, Eun Kyoung ^a,c   Jin, Taewon ^a,c,d   Lee, Seung Min ^e   Kim, Soo Hyuk ^a,c,d   Choi, Eun Young ^a,c,d   Shin, Min Jeong ^e   Lee, Kyung Hye ^a,c,d   Jang, Yangsoo ^a,b,c,d  

^a Cardiovascular Research Institute

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Korea University   (South Korea)

Author keywords

Cathepsin L; Cell migration; Endothelium; Fibroblast growth factor 2; JNK mitogen activated protein kinases

Indexed keywords

ADENOVIRUS VECTOR; BASIC FIBROBLAST GROWTH FACTOR; CATHEPSIN L; CATHEPSIN L INHIBITOR; ENZYME INHIBITOR; INTERSTITIAL COLLAGENASE; NEUTRALIZING ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BFGF GENE; CELL LEVEL; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE; GENE CONSTRUCT; GENE FUNCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LACZ GENE; MUSCLE CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SKELETAL MUSCLE;

EID: 79955649678     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2011.43.4.022     Document Type: Article

References (37)

1. Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 2005;59:102-6
2. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008;16:585-601
3. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007;97:336-42
4. Blackburn JS, Brinckerhoff CE. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am J Pathol 2008;173:1736-46
5. Chen B, Qin J, Wang H, Magdalou J, Chen L. Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits. Exp Mol Med 2010;42:684-95
6. Chen L, Endler A, Shibasaki F. Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Exp Mol Med 2009;41:849-57
7. Collette J, Bocock JP, Ahn K, Chapman RL, Godbold G, Yeyeodu S, Erickson AH. Biosynthesis and alternate targeting of the lysosomal cysteine protease cathepsin L. Int Rev Cytol 2004;241:1-51
8. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci 2009;14:4575-87
9. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Nöel A, Foidart JM. The proor antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002;16:147-54
10. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000;19:1187-94
11. Fujii T, Yonemitsu Y, Onimaru M, Inoue M, Hasegawa M, Kuwano H, Sueishi K. VEGF function for upregulation of endogenous PlGF expression during FGF-2-mediated therapeutic angiogenesis. Atherosclerosis 2008;200:51-7
12. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007;6:60-4
13. Kaneko T, Fujii S, Matsumoto A, Goto D, Ishimori N, Watano K, Furumoto T, Sugawara T, Sobel BE, Kitabatake A. Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid. Arterioscler Thromb Vasc Biol 2002;22:855-60
14. Kim JW, Kim TD, Hong BS, Kim OY, Yoon WH, Chae CB, Gho YS. A serum-stable branched dimeric anti-VEGF peptide blocks tumor growth via anti-angiogenic activity. Exp Mol Med 2010;42:514-23
15. Kondoh K, Koyama H, Miyata T, Takato T, Hamada H, Shigematsu H. Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor. Cardiovasc Res 2004;61: 132-42
16. Lah TT, Durán Alonso MB, Van Noorden CJ. Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 2006;6:257-79
17. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007;100:782-94
18. Le NT, Xue M, Castelnoble LA, Jackson CJ. The dual personalities of matrix metalloproteinases in inflammation. Front Biosci 2007;12:1475-87
19. Markkanen JE, Rissanen TT, Kivela A, Yla-Herttuala S. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy. Cardiovasc Res 2005;65:656-64
20. Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 2006;4:101-16
21. Ninomiya M, Koyama H, Miyata T, Hamada H, Miyatake S, Shigematsu H, Takamoto S. Ex vivo gene transfer of basic fibroblast growth factor improves cardiac function and blood flow in a swine chronic myocardial ischemia model. Gene Ther 2003;10:1152-60
22. Nishikage S, Koyama H, Miyata T, Ishii S, Hamada H, Shigematsu H. In vivo electroporation enhances plasmid-based gene transfer of basic fibroblast growth factor for the treatment of ischemic limb. J Surg Res 2004;120:37-46
23. Onimaru M, Yonemitsu Y, Tanii M, Nakagawa K, Masaki I, Okano S, Ishibashi H, Shirasuna K, Hasegawa M, Sueishi K. Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 2002; 91:923-30
24. Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 2008;29:22-8
25. Palmon A, Roos H, Edel J, Zax B, Savion N, Grosskop A, Pitaru S. Inverse dose-and time-dependent effect of basic fibroblast growth factor on the gene expression of collagen type I and matrix metalloproteinase-1 by periodontal ligament cells in culture. J Periodontol 2000;71:974-80
26. Pardo A, Selman M. MMP-1: the elder of the family. Int J Biochem Cell Biol 2005;37:283-8
27. Pintucci G, Moscatelli D, Saponara F, Biernacki PR, Baumann FG, Bizekis C, Galloway AC, Basilico C, Mignatti P. Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells. FASEB J 2002;16:598-600
28. Pulukuri SM, Rao JS. Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol 2008; 32:757-65
29. Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 2005;11:1251-66
30. Stoka V, Turk V, Turk B. Lysosomal cysteine cathepsins: signaling pathways in apoptosis. Biol Chem 2007;388: 555-60
31. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29
32. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, Vajkoczy P, Hofmann WK, Peters C, Pennacchio LA, Abolmaali ND, Chavakis E, Reinheckel T, Zeiher AM, Dimmeler S. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005;11: 206-13
33. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006;26:716-28
34. Watanabe A, Kurabayashi M, Arai M, Sekiguchi K, Nagai R. Combined effect of retinoic acid and basic FGF on PAI-1 gene expression in vascular smooth muscle cells. Cardiovasc Res 2001;51:151-9
35. Xie J, Bian H, Qi S, Xu Y, Tang J, Li T, Liu X. Effects of basic fibroblast growth factor on the expression of extracellular matrix and matrix metalloproteinase-1 in wound healing. Clin Exp Dermatol 2008;33:176-82
36. Yang Z, Cox JL. Cathepsin L increases invasion and migration of B16 melanoma. Cancer Cell Int 2007;7:8
37. Yla-Herttuala S. An update on angiogenic gene therapy: vascular endothelial growth factor and other directions. Curr Opin Mol Ther 2006;8:295-300